• 1
    Calvert CA, Meurs KM. Doberman Pinscher occult cardiomyopathy. In: Bonagura JD, Kirk RW, eds. Current Veterinary Therapy XIII: Small Animal Practice. Philadelphia, PA: WB Saunders; 2000:756760.
  • 2
    Hazlett MJ, Maxie MG, Allen DG, Wilcock BP. A retrospective study of heart disease in Doberman Pinscher dogs. Can Vet J 1983;24:205210.
  • 3
    O'Grady MR, Horne R. The prevalence of dilated cardiomyopathy in Doberman Pinschers: A 4.5 year follow-up J Vet Int Med 2012;12:199.
  • 4
    Wess G, Schulze A, Butz V, et al. Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups. J Vet Intern Med 2010;24:533538.
  • 5
    O'Grady MR, O'Sullivan ML. Dilated cardiomyopathy: An update. Vet Clin North Am Small Anim Pract 2004;34:11871207.
  • 6
    Tidholm A, Jonsson L. A retrospective study of canine dilated cardiomyopathy (189 cases). J Am Anim Hosp Assoc 1997;33:544550.
  • 7
    Wess G, Butz V, Mahling M, Hartmann K. Evaluation of N-terminal pro-B-type natriuretic peptide as a diagnostic marker of various stages of cardiomyopathy in Doberman Pinschers. Am J Vet Res 2011;72:642649.
  • 8
    Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008;232:14961503.
  • 9
    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321328.
  • 10
    Fagan TJ.Letter: Nomogram for Bayes theorem. N Engl J Med 1975;293:257.
  • 11
    Ettinger SJ, Farace G, Forney SD, et al. Evaluation of plasma N-terminal pro-B-type natriuretic peptide concentrations in dogs with and without cardiac disease. J Am Vet Med Assoc 2012;240:171180.
  • 12
    Oyama MA, Sisson DD, Solter PF. Prospective screening for occult cardiomyopathy in dogs by measurement of plasma atrial natriuretic peptide, B-type natriuretic peptide, and cardiac troponin-I concentrations. Am J Vet Res 2007;68:4247.
  • 13
    Akobeng AK. Understanding diagnostic tests 2: Likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr 2007;96:487491.
  • 14
    Lord PF, Hansson K, Carnabuci C, et al. Radiographic heart size and its rate of increase as tests for onset of congestive heart failure in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2011;25:13121319.
  • 15
    O'Sullivan ML, O'Grady MR, Minors SL. Plasma big endothelin-1, atrial natriuretic peptide, aldosterone, and norepinephrine concentrations in normal Doberman Pinschers and Doberman Pinschers with dilated cardiomyopathy. J Vet Intern Med 2007;21:9299.
  • 16
    Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: A meta-analysis. Eur J Heart Fail 2009;11:958966.
  • 17
    Wess G, Simak J, Mahling M, Hartmann K. Cardiac troponin I in Doberman Pinschers with cardiomyopathy. J Vet Intern Med 2010;24:843849.
  • 18
    Fonfara S, Loureiro J, Swift S, et al. Cardiac troponin I as a marker for severity and prognosis of cardiac disease in dogs. Vet J 2010;184:334339.
  • 19
    Chetboul V, Serres F, Tissier R, et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009;23:984994.
  • 20
    Moonarmart W, Boswood A, Luis F. V, et al. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010;51:8496.
  • 21
    Tigen K, Karaahmet T, Cevik C, et al. Prognostic utility of anemia and pro-B-type natriuretic peptide in patients with nonischemic dilated cardiomyopathy and normal renal function. Am J Med Sci 2009;337:109115.
  • 22
    Tang WH, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem 2008;41:210221.
  • 23
    Tigen K, Karaahmet T, Kahveci G, et al. N-terminal pro brain natriuretic peptide to predict prognosis in dilated cardiomyopathy with sinus rhythm. Heart Lung Circ 2007;16:290294.
  • 24
    Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270276.
  • 25
    Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:18071816.
  • 26
    Tidholm A, Haggstrom J, Borgarelli M, Tarducci A. Canine idiopathic dilated cardiomyopathy. Part I: Aetiology, clinical characteristics, epidemiology and pathology. Vet J 2001;162:92107.
  • 27
    Sisson D.Myocardial Diseases of Dogs. In: Textbook of Canine and Feline Cardiology. Fox PR, Sisson DD, Moise NM, eds. WB Saunders, Philadelphia, PA:1999;27:581-620.